Use of Physiologically Based Pharmacokinetic (PBPK) Modeling for Predicting Drug-Food Interactions: an Industry Perspective.
Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Oxazepam, Naloxone, and Zidovudine.
IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.
Prediction characteristics of oral absorption simulation software evaluated using structurally diverse low solubility drugs.
Development of a Physiologically Based Pharmacokinetic Model for Prediction of Pramipexole Pharmacokinetics in Parkinson's Disease Patients With Renal Impairment.
Application of Physiologically-Based Pharmacokinetic Modeling to Predict Gastric pH-Dependent Drug–Drug Interactions for Weak Base Drugs.
A Physiologically Based Pharmacokinetic Model of Ertapenem in Pediatric Patients With Renal Impairment.
Physiologically based pharmacokinetic modelling of oxycodone drug-drug interactions.
A combined in vitro in-silico approach to predict the oral bioavailability of borderline BCS Class II/IV weak base Albendazole and its main metabolite Albendazole Sulfoxide.
Physiologically based pharmacokinetic modeling to understand the absorption of risperidone orodispersible film.
Prediction of ARA/PPI Drug-Drug Interactions at the Drug Discovery and Development Interface.
Evaluation of Generic Methods to Predict Human Pharmacokinetics Using Physiologically Based Pharmacokinetic Model for Early Drug Discovery of Tyrosine Kinase Inhibitors.
Ren HC, Sai Y, Chen T. Eur J Drug Metab Pharmacokinet. Jul 23, 2018. IF=1.913
Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review.
Prediction of Losartan-Active Carboxylic Acid Metabolite Exposure Following Losartan Administration Using Static and Physiologically Based Pharmacokinetic Models.
Exploring and validating physicochemical properties of mangiferin through GastroPlus® software.
IMI–Oral biopharmaceutics tools project– Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results.
IMI–Oral biopharmaceutics tools project– Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes.
Evaluation of the GastroPlus™ Advanced Compartmental and Transit (ACAT) Model in Early Discovery.
In silico modeling of gastrointestinal drug absorption: predictive performance of three physiologically based absorption models.
Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds.
Predicting Pharmacokinetic Profiles Using In Silico Derived Parameters.
Case Studies for Practical Food Effect Assessments across BCS/BDDCS Class Compounds using In Silico, In Vitro, and Preclinical In Vivo Data.
Simulation of human intravenous and oral pharmacokinetics of 21 diverse compounds using physiologically based pharmacokinetic modelling.